“We expect this will take on average two to three months per patient.”

In context

“hare within the S1P class and continued volume growth in the very competitive ulcerative colitis market. Outside the U.S, sales increased mainly due to demand in MS. Turning to Sotyktu, underlying launch trends remain strong. Sales in the quarter were $66 million, which included a clinical supply purchase of approximately $30 million, and we saw continued strong volume demand during the quarter. With over 38,000 script equivalents dispensed since launch, we’ve delivered over 15,000 script equivalents in the U.S. during the third quarter. Within the oral category, our share is now roughly 40%, reinforcing that Sotyktu is establishing a position as the oral of choice in this market, and we are making progress converting covered CVS patients from the free drug program to commercial dispense. We expect this will take on average two to three months per patient. Building on our momentum, we continue to expect the further strengthening of access next year. Now moving to the P&L on Slide 19, I will focus my remarks on a few non-GAAP key line items, having just covered sales performance. Compared to Q2, gross margin was favorably impacted by product mix. Acquired in-process R&D in the quarter was $80 million, which was partially offset by $12 million of licensing income, resulting in a net impact of $0.03 of EPS. The reduction in the effective tax rate during the quarter was primarily due to recently issued Section 174 guidance regarding deductibility of certain research and development expenses. This resulted in an adjustment in the quarter to our estimated tax rate. Overall, third quarter earnings per share was $2.00 per share, growing approximate”